VibroniX Secures Nearly RMB 100 Million Series A+ Financing to Accelerate Commercialization of Spectroscopy Instruments and Industrial Solutions

VCBeat has learned that Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. (hereinafter referred to as “Weibang Zhendian”) has announced the completion of its Series A+ financing round, raising nearly RMB 100 million. The round was led by KinghandCapital Management(beijing)CO.,Ltd., with existing investor FreeS Fund making an oversubscribed follow-on investment and Founder H Fund participating as a co-investor. The proceeds will be used to accelerate the commercialization and scale-up of Weibang Zhendian’s spectral analysis products, iterate and develop solutions for the industrial sector, and advance R&D in ultra-multiplex immunohistochemistry applications. Genesis Partners served as the exclusive long-term financial advisor to Weibang Zhendian.

Weibang Zhendian is a high-tech enterprise centered on innovations in molecular vibrational spectroscopy, dedicated to developing high-end domestically produced spectral analysis and imaging products as well as a precision medical diagnosis platform.Weibang Zhendian was established in 2017, with subsidiaries including Zhendian (Suzhou) Medical Technology Co., Ltd. and Weipeng (Suzhou) Medical Device Co., Ltd. The company has been recognized as a National High-Tech Enterprise, received the title of Science and Technology Leading Talent in Suzhou Industrial Park, and won the Second Prize in the China Medical Device Innovation and Entrepreneurship Competition. The core team possesses extensive R&D experience in spectral technology, optical imaging, and optoelectronic analysis, boasting globally independent and controllable leading technical capabilities. The company holds more than 10 independently developed core patents and has exclusive authorization for 16 patents from world-renowned research institutions and universities. With over 1,000 square meters of R&D and production space, the company has established a sound design and development system as well as a quality control system, and has obtained medical device quality system certification and GMP certification.

Currently, the global markets for scientific instruments and spectroscopic instruments are experiencing continuous growth. In 2020, the global market size for scientific instruments was approximately USD 64 billion, with China’s market size reaching about USD 10 billion (accounting for roughly 15% of the global total). The global market for spectroscopic instruments stood at approximately USD 9 billion, while China’s market size was around USD 1 billion (representing about 10% of the global share). According to a research report by Emergen Research, the global spectroscopy market is projected to reach USD 19 billion by 2030, with a compound annual growth rate (CAGR) of approximately 6%. China’s spectroscopic instrument market is expected to maintain a higher growth trajectory in the coming years, with its market size anticipated to reach USD 3 billion.

Against the backdrop of a booming global market for spectroscopic instruments, China’s long-standing reliance on imported brands in the fields of high-end spectroscopy and microscopic imaging is undergoing a significant transformation. Imported products are typically expensive, suffer from slow technological updates, and offer inadequate after-sales service. To address these challenges, proactive national policies and growing market demand have created unprecedented opportunities for the development of domestically produced scientific instruments. In recent years, the Chinese government has frequently introduced favorable policies to vigorously encourage research institutions to procure domestically made equipment and support the advancement of China’s domestic scientific instrument industry.

In this trend, the core members of Weibang Zhendian come from the world's top teams in spectral analysis and imaging technology. They have mastered complex optical path design at the underlying level of spectral technology and ultra-sensitive opto-mechanical-electrical detection technology, building a fast, sensitive, and high-throughput spectral analysis and imaging technology platform. This platform has enormous potential to replace existing solutions and expand into emerging application scenarios.

Weibang Zhendian, leveraging its three independently developed spectral technology platforms—the Coherent Raman Technology Platform, the Transient Absorption Technology Platform, and the Instantaneous Laser Infrared Technology Platform—can significantly enhance core performance metrics, including specificity, sensitivity, resolution, and imaging speed.Among them, Weibang Zhendian’s coherent Raman technology platform offers a 10-fold increase in sensitivity compared to spontaneous Raman.⁶times, with an imaging resolution of 200–500 nm. It offers chemical specificity by specifically identifying molecular vibrations, enabling non-destructive, label-free imaging. This approach avoids the phototoxicity and photobleaching associated with fluorescence, which can preclude statistical analysis. Compared with techniques such as chromatography–mass spectrometry, it enables single-cell in situ analysis comparable to fluorescence imaging. Furthermore, the company’s transient laser infrared technology platform boasts significant advantages, including high resolution, rapid imaging, high sensitivity and signal-to-noise ratio, and effective water background suppression. The transient absorption technology platform achieves a sensitivity of up to 10^-7OD (100 μs integration time), ultra-high imaging speed with scanning frequency up to 10 FPS, leading industry development.

In terms of commercialization progress, Weibang Zhendian’s engineered products currently address analytical and imaging needs across multiple fields, including life sciences scenarios (such as metabolic research, oncology research, ultra-multiplex immunohistochemistry, and drug analysis), synthetic biology research and production quality control scenarios, materials science scenarios (including graphene, organic optoelectronic materials, microcrystals, and silicon carbide), and environmental science scenarios (such as environmental monitoring and microplastic analysis). The company provides superior domestically produced analytical and imaging tool solutions tailored to scientific research, industrial monitoring, and medical testing applications. It has gained full recognition from academic and research institution customers, achieved breakthroughs with industrial clients, and entered a phase of rapid sales growth.

Dr. Wang Pu, CEO of Weibang Zhendian, stated“We extend our gratitude to Kinghand Capital, FreeS Fund, and Founder H Fund for their support and trust. This financing will further solidify Weibang Zhendian’s first-mover technological advantage in the spectral instrumentation sector, accelerate our domestic and international expansion, and provide sustained momentum for developing engineered products across various application scenarios. Leveraging rapid and sensitive spectral innovation technologies, Weibang Zhendian will continue to empower customers and industries in fields such as life sciences, synthetic biology research and production quality control, materials science, and environmental science. Meanwhile, we will deepen collaborations with partners to drive continuous progress and innovation in the scientific instrumentation field, making greater contributions to human health and advancing the localization of scientific instruments in China.”

KinghandCapital stated“Kinghand Capital has long focused on technological transformation opportunities in the field of hard-tech healthcare. Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. masters the world’s most advanced spectral analysis and imaging technologies, along with robust product engineering capabilities. By continuously enriching its product lines and solution matrix, the company is committed to providing researchers and enterprises in hard-tech sectors such as healthcare, semiconductors, and new energy with the highest-quality high-end domestic tools, thereby filling the gap in China’s high-end spectral analysis and imaging market. Kinghand Capital is pleased to support Weibang Zhendian in accelerating its business development, leveraging capital strength and industrial resources to help outstanding enterprises grow rapidly and realize the blueprint for new infrastructure in biomedicine and health hard-tech across society.”

Wang Lei, Partner at FreeS Fund, and Li Gang, Head of Early-Stage Projects, stated“Traditional optical imaging is approaching its physical limits, making optical manipulation and computational optics the new development trends. Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. has established stimulated microscopy as its core technology platform. Leveraging a profound understanding of optical nonlinear effects, precise light source control, and high-throughput computing capabilities, the company has overcome the sensitivity and speed limitations of traditional methods, thereby achieving future-oriented, non-destructive, non-invasive, high-precision quantitative imaging analysis of matter. Furthermore, as a leading Chinese enterprise achieving mass shipments in the fields of advanced optics and microscopy, Weibang Zhendian is beginning to carve out a niche in the ultra-high-end optical instrument market, which has long been dominated by foreign companies. Weibang Zhendian is a representative portfolio company of FreeS Fund in the interdisciplinary field of computation and optics. We look forward to Weibang Zhendian continuing to leverage its advanced technology platform and innovative capabilities to explore, advance, and break new ground in optical technology, achieving comprehensive breakthroughs spanning from biology to healthcare, and from clinical applications to industrial use.”

Mou Jingrui, Managing Director of Founder H Fund“He stated: ‘As an innovative cutting-edge optical technology, coherent Raman microscopy features high resolution, high sensitivity, and strong interference resistance. It enables efficient, non-destructive, multi-parametric detection, providing a more efficient and convenient analytical approach for life sciences and basic medical research. As a leading high-tech enterprise in the field of coherent Raman technology both domestically and internationally, Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. offers an unprecedentedly efficient and rapid tool for applications such as multiplex protein detection, molecular interactions, and synthetic biology. This novel tool serves as an effective aid to frontier scientific research in the life sciences and fills a gap in this related field both in China and abroad. We are delighted to have the opportunity to collaborate with Weibang Zhendian, aligning with the national policy direction aimed at resolving critical technological bottlenecks (“chokehold” issues) essential for the rise of major powers, and jointly contributing to the advancement of high-end precision instruments in the life sciences sector.’”

Yuan Yi Capital stated“The continuous advancement of cutting-edge spectroscopic technologies is constantly unlocking and driving greater granularity and deeper cognitive understanding in human research of the microscopic world. The development of domestically produced, self-controllable high-end spectroscopic instruments is a key support and an inevitable requirement for fostering new quality productive forces. Leveraging transformative, source-level technological innovations in spectroscopy, Suzhou Weibang Zhendian Optoelectronic Technology Co., Ltd. has built a multi-product tool matrix featuring high sensitivity, high resolution, and rapid analysis, providing next-generation analytical and imaging solutions for diverse scenarios in scientific research, life sciences, industry, and clinical practice. This has earned high recognition from the academic community and customers alike. Yuan Yi Capital is honored to have supported the company in completing this round of financing and looks forward to Weibang Zhendian continuing to lead the sustained development of the high-end spectroscopic analysis and imaging field.”

Kinghand Capital is a leading private equity investment firm focused on the healthcare sector, dedicated to leveraging capital and industrial resources to accelerate the growth of outstanding healthcare enterprises, deliver superior medical products and services to society, and advance human health.

Currently, Kinghand Capital manages 18 RMB-denominated funds and 4 USD-denominated funds, with investments in 86 high-quality projects. Among these, 16 portfolio companies have completed initial public offerings (IPOs), including one that has received registration approval from the China Securities Regulatory Commission (CSRC). Notable IPOs include Aier Eye Hospital Group’s subsidiary Purui Ophthalmology (301239), Jinxin Fertility Group (HK.1951), Sino Medical Sciences Technology (688108), Tinavi Medical Technologies (688277), Viva Biotech Holdings (HK.1873), Innotest Diagnostics (688253), LBP Medicine (688393), and Angies (688581). As of 2024, three additional portfolio companies have filed for IPOs, and more than 10 invested enterprises are expected to enter the IPO process within the next three years.

FreeS Fund is committed to mobilizing all available capital, technology, and resources to invest in outstanding startups and help them grow into great enterprises with long-term social and commercial value. FreeS Fund focuses on early-stage and growth-early-stage investments, with key investment areas including Consumer/TMT, Hard Tech, and Biopharmaceuticals. Research-driven and innovation-oriented, FreeS Fund has developed a systematic investment strategy through continuous exploration—seeking unique investment opportunities at the intersection of disciplines.

Founder H FundFounded in August 2010, Founder H Fund is a wholly-owned subsidiary of Founder Securities Co., Ltd. (601901.SH). It is a professional private equity subsidiary of a securities company engaged in private fund management and related businesses, registered and filed with the Asset Management Association of China (Registration No.: PT2600011619). With a registered and paid-in capital of RMB 2 billion, Founder H Fund manages assets totaling nearly RMB 20 billion and has invested in over 130 companies. Its core management team possesses extensive experience in industrial incubation and financial investment. The company has been consecutively honored for many years with awards such as "Top 10 Best Private Equity Subsidiaries of Securities Companies in China" and "Top 100 Best Private Equity Investment Institutions in China." Multiple projects have been recognized among the "Top 10 Best Investment Cases" and "Top 10 Best Exit Cases" in sectors including China’s medical and health services industry, advanced manufacturing and high-tech industry, artificial intelligence and big data industry, and internet industry.Founder H Fund features a robust corporate governance structure and a specialized, flat organizational hierarchy. Headquartered in Beijing, the company maintains offices in Shanghai, Hefei, Changsha, Wuhan, and other cities. Leveraging the backing of a large listed financial enterprise, deep industry accumulation, excellent industrial empowerment resources, and substantial capital, Founder H Fund has achieved rapid growth over the past 12 years. Striving to become a leading investment institution widely trusted by clients, it aims to facilitate China’s industrial upgrading and promote the sustainable growth of China’s competitive industries.

Founded in 2021, Yuanyi Capital is dedicated to providing comprehensive capital market solutions for enterprises in the healthcare sector, leveraging an international perspective alongside rich local resources and insights. The firm boasts a diverse team with extensive backgrounds in investment banking, corporate finance, industry operations, private equity, and strategic and management consulting. Committed to delivering high-caliber services and endorsements, Yuanyi Capital aims to enhance its clients’ capabilities and efficiency in the capital markets. The company has accumulated substantial transaction experience and industry expertise in specialized segments such as innovative therapies, medical devices, upstream life sciences, consumer healthcare, and digital health, having led over 100 transactions with a cumulative value exceeding USD 6 billion. Yuanyi Capital looks forward to growing alongside its clients, portfolio companies, and industry partners, striving to become the most trusted companion for all stakeholders.